Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 12/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48409 | 1.00 | KIF11 (0.73) | KIF11ALDH1A1SMN1; SMN2KDM1AKDM4E | |
| SCHEMBL18230875 | 0.84 | KIF11 (0.54) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 | |
| SCHEMBL67628 | 0.83 | KIF11 (0.58) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 | |
| SCHEMBL10299815 | 0.83 | KIF11 (0.58) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 | |
| SCHEMBL472408 | 0.83 | KIF11 (0.56) | KIF11ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL20740835 | 0.83 | KIF11 (0.56) | KIF11KDM1ACYP11B1CYP11B2 | |
| SCHEMBL3034920 | 0.82 | KIF11 (0.51) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 | |
| SCHEMBL30874807 | 0.82 | KIF11 (0.51) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 | |
| SCHEMBL16846737 | 0.82 | KIF11 (0.51) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 | |
| SCHEMBL21402590 | 0.81 | KIF11 (0.56) | KIF11ALDH1A1KDM1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680608-A1 | 2,6-DIHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE DERIVATIVES AS ANTI-MALARIAL AGENTS | MMV Medicines for Malaria Venture (CH) | 2026-01-21 | — | — | EP | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250179083-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2025-06-05 | — | — | US | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4436955-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| CN-117062804-A | 1, 3-substituted cyclobutyl derivatives and their use | 诺华股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-116710431-A | Small molecule compounds and compositions | 泰洛治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116675673-A | 3, 5-bis (aryl) -4-methylphenidate derivatives, preparation method and application thereof | 滨州医学院 | 2023-09-01 | — | — | CN | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| CN-110062758-B | Bicyclic dihydropyrimidine-carboxamide derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2022109209-A1 | SMALL MOLECULE COMPOUNDS AND COMPOSITIONS | TELO THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220064167-A1 | IMIDAZO-PYRAZOLE CARBOXAMIDE DERIVATIVES AS ANTICANCER AGENTS AND THE SYNTHESIS THEREOF | AVIDIN KFT. (HU) | 2022-03-03 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | KIF11 2721/4885ALDH1A1 3628/4885SMN1; SMN2 126/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | KIF11 2721/4885ALDH1A1 3628/4885SMN1; SMN2 126/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | KIF11 2721/4885ALDH1A1 3628/4885SMN1; SMN2 126/4885 |
| US-20250179083-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | KIF11 1995/4885ALDH1A1 4279/4885SMN1; SMN2 4775/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | KIF11 3738/4885ALDH1A1 411/4885SMN1; SMN2 2461/4885 |
| US-20220064167-A1 | IMIDAZO-PYRAZOLE CARBOXAMIDE DERIVATIVES AS ANTICANCER AGENTS AND THE SYNTHESIS THEREOF | MYD88, MCL1, MYADM | KIF11 4037/4885ALDH1A1 1536/4885SMN1; SMN2 395/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | KIF11 2721/4885ALDH1A1 3628/4885SMN1; SMN2 126/4885 |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | KIF11 2721/4885ALDH1A1 3628/4885SMN1; SMN2 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.